DDInter704 DDInter714
Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.
Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019.
Everolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fedratinib
Everolimus {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Mirabegron
Mirabegron {u} may cause a minor interaction that can limit clinical effects when taken with {v} Fedratinib
Everolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} may cause a minor interaction that can limit clinical effects when taken with {v} Doravirine
Doravirine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Fedratinib
Everolimus {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 2D6 Inhibitors
Cytochrome P450 2D6 Inhibitors {u} (Pharmacologic Class) includes {v} (Compound) Mirabegron
Mirabegron {u} may cause a minor interaction that can limit clinical effects when taken with {v} Fedratinib
Everolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ribociclib
Ribociclib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Fedratinib
Everolimus {u} (Compound) causes {v} (Side Effect) Leukocytoclastic vasculitis
Leukocytoclastic vasculitis {u} (Side Effect) is caused by {v} (Compound) Mirabegron
Mirabegron {u} may cause a minor interaction that can limit clinical effects when taken with {v} Fedratinib
Everolimus {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 2D6 Inhibitors
Cytochrome P450 2D6 Inhibitors {u} (Pharmacologic Class) includes {v} (Compound) Desvenlafaxine
Desvenlafaxine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fedratinib
Everolimus {u} (Compound) causes {v} (Side Effect) Leukocytoclastic vasculitis
Leukocytoclastic vasculitis {u} (Side Effect) is caused by {v} (Compound) Imatinib
Imatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fedratinib
Everolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Verapamil
Verapamil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Fedratinib
Everolimus {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Macitentan
Macitentan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fedratinib
Everolimus (Compound) resembles Sirolimus (Compound) and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Everolimus (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Mirabegron (Compound) and Mirabegron may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Everolimus (Compound) resembles Sirolimus (Compound) and Sirolimus may cause a minor interaction that can limit clinical effects when taken with Doravirine and Doravirine may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Everolimus (Compound) is included by Cytochrome P450 2D6 Inhibitors (Pharmacologic Class) and Cytochrome P450 2D6 Inhibitors (Pharmacologic Class) includes Mirabegron (Compound) and Mirabegron may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Everolimus (Compound) resembles Sirolimus (Compound) and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Everolimus (Compound) causes Leukocytoclastic vasculitis (Side Effect) and Leukocytoclastic vasculitis (Side Effect) is caused by Mirabegron (Compound) and Mirabegron may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Everolimus (Compound) is included by Cytochrome P450 2D6 Inhibitors (Pharmacologic Class) and Cytochrome P450 2D6 Inhibitors (Pharmacologic Class) includes Desvenlafaxine (Compound) and Desvenlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Everolimus (Compound) causes Leukocytoclastic vasculitis (Side Effect) and Leukocytoclastic vasculitis (Side Effect) is caused by Imatinib (Compound) and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Everolimus (Compound) resembles Sirolimus (Compound) and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Verapamil and Verapamil may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Everolimus (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Macitentan (Compound) and Macitentan may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib